In Vitro and In Vivo Evaluation of the Effects of Drug 2c and Derivatives on Ovarian Cancer Cells

• Egile Nagusiak: Marianna Maddaloni (Egilea), Rossella Farra (Egilea), Barbara Dapas (Egilea), Fulvia Felluga (Egilea), Fabio Benedetti (Egilea), Federico Berti (Egilea), Sara Drioli (Egilea), Mattia Vidali (Egilea), Maja Cemazar (Egilea), Urska Kamensek (Egilea), Claudio Brancolini (Egilea), Erminio Murano (Egilea), Francesca Maremonti (Egilea), Mario Grassi (Egilea), Alice Biasin (Egilea), Flavio Rizzolio (Egilea), Enrico Cavarzerani (Egilea), Bruna Scaggiante (Egilea), Roberta Bulla (Egilea), Andrea Balduit (Egilea), Giuseppe Ricci (Egilea), Gabriella Zito (Egilea), Federico Romano (Egilea), Serena Bonin (Egilea), Eros Azzalini (Egilea), Gabriele Baj (Egilea), Domenico Tierno (Egilea), Gabriele Grassi (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: The identification of novel therapeutic strategies for ovarian cancer (OC), the most lethal gynecological neoplasm, is of utmost urgency. Here, we have tested the effectiveness of the compound 2c (4-hydroxy-2,6-bis(4-nitrobenzylidene)cyclohexanone 2). 2c interferes with the cysteine-depe...